GSK Receives Approvable Letter For Once-Daily Formulation Of Requip
This article was originally published in The Pink Sheet Daily
Executive Summary
Extended-release version will reduce Parkinson’s disease patients’ “off time” by about two hours a day, clinical data show.
You may also be interested in...
Requip XL User Fee Date Pushed Back To Second Quarter
FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.
Requip XL User Fee Date Pushed Back To Second Quarter
FDA needs additional time to review food effect data from GlaxoSmithKline for the once-daily Parkinson's treatment.
FDA Approves Sciele’s Sular Sustained-Release For Hypertension
Approval comes roughly six months ahead of patent expiration for Sular immediate-release.